Australian biotech researchers and entrepreneurs are being encouraged to apply for funding from the country’s first national biotech incubator, CUREator.
The race is on: Eli Lilly has begun the application for the approval of its Alzheimer's disease (AD) treatment in the US, potentially setting it up against rival Biogen's recently approved Aduhelm.
Pfizer and BioNTech have completed long-range drone deliveries of their mRNA COVID-19 vaccine: with partner Zipline claiming to be the first to deliver vaccines in this way at a national scale.
The Cell and Gene Therapy Catapult and Deep Science Ventures have formed a partnership aimed at creating innovative approaches to address barriers in the Advanced Therapy Medicinal Products (ATMP) industry.
Dutch stem cell company Neuroplast has announced positive Phase 1 results for its Neuro-Cells investigational stem cell treatment in patients suffering from Traumatic Spinal Cord Injury (TSCI).
The COVID-19 pandemic has reversed years of global progress in tackling tuberculosis and - for the first time in over a decade - TB deaths have increased. Research breakthroughs – such as new vaccines – are needed to rapidly reduce the number of new cases...
CEPI, the Coalition for Epidemic Preparedness Innovations, has announced the first funding awards under a $200m program to advance development of vaccines against SARS-CoV-2 variants and other betacoronaviruses.
Human papillomavirus (HPV) vaccines reduce cervical cancer rates by 87% in women who were offered the jab between the ages of 12-13, according to a study which analysed data from England's HPV vaccine program.
The porphyria therapies market is projected to grow at an annualized rate of 10.97% during the period 2021-2030, claims a new report from Roots Analysis.
CPhI Worldwide will see Gerresheimer showcase its latest developments in primary packaging, drug delivery systems for newly developed biologics along with medical and diagnostic products.
During CPhI Worldwide, leaders from two organizations will outline how CM is taking off, potential benefits, and how to clear common obstacles to adoption.
An expert from the specialty chemicals firm (and CPhI Worldwide speaker) explains trends and developments in excipients and how they drive advancements.
A clinical trial is exploring the use of the Oxford/AstraZeneca COVID-19 vaccine as an intranasal vaccine: seeing if the new route of administration could improve protection against infection and transmission.
Researchers at Stanford University and the University of North Carolina Chapel Hill are developing a microneedle vaccine patch that they believe could deliver a stronger immune response than a vaccine shot.
Biolife Solutions and its subsidiary SciSafe have opened a new 40,000 square-foot biorepository Center of Excellence in Amsterdam, located next to Schiphol Airport.
Absci Corporation says its newly opened campus in Vancouver, Washington, in the US, expands its ability to accelerate discovery and development of biologic drugs.
AION Labs, a new innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, has announced a global call for application to identify biomedical scientists and inventors to form a new startup at...
Locus Biosciences has entered a credit facility of up to US$25m with Hercules Capital, which it says will support the expansion of its precision engineered bacteriophage discovery platform engine and in-house manufacturing capacity.
Charles River and ATEM Structural Discovery (ATEM) are collaborating to provide access to cryo-electron microscopy (cryo-EM), a technique that visualizes molecules and proteins in atomic resolution to determine their 3D shape.
Announcing a new partnership, Autolomous and Vineti say they are integrating their technology to ensure scalability when cell and gene therapies become standard of care.
Touchlight, a synthetic DNA producer, says it has received the first phase of planning approval for breaking ground on its new research and manufacturing facility in Hampton, UK.
The new alliance will focus on the development and manufacturing of complex medicines including biologics, vaccines, nucleic acids and cell and gene therapies; as well as looking to launch companies to advance the manufacture of such medicines.
AION Labs, a ‘first-of-its-kind’ innovation lab that will create and adopt AI technology to transform the process of drug discovery and development, has officially launched this month.
CureVac is withdrawing its first-generation COVID-19 vaccine candidate, CVnCoV, from regulatory review: instead it is re-allocating its efforts to its second-generation vaccine program with GSK. ‘The goal has not changed, but the requirements to effectively...
AstraZeneca's AZD7442, a long acting antibody (LAAB) combination, achieved a statistically significant reduction in severe COVID-19 or death compared to placebo in non-hospitalised patients with mild-to-moderate symptomatic COVID-19.
Absci Corp, a synthetic biology firm, is partnering with pharma company, EQRx, to jointly engineer and develop several clinical candidates across multiple therapeutic areas, including oncology and immunology.
VGXI, Inc, a provider of plasmid DNA manufacturing and development services, says multiple construction milestones have been reached for its new headquarters and manufacturing facility in Texas.
M Ventures, the strategic, corporate venture capital arm of Merck KGgA, continues to fund iOmx Therapeutics AG, a company developing cancer therapeutics based on next generation immune checkpoint targets.
Marken, the clinical trial logistics subsidiary of UPS Healthcare, is adding significant capacity to support increased demand for its clinical drug supply chain services, particularly for cell and gene clinical trials.
While several vaccines protect against meningitis, there remains an urgent need for innovation, funding and research to develop more meningitis-preventive vaccines, according to a new report from the WHO.
Moderna is investing in a 462,000 square foot building in Cambridge, Massachusetts, to create a purpose-built space for scientific research and development labs.
The operation of the 1.5 million square-foot biologics manufacturing site in Lengnau, Switzerland is part of a strategic partnership agreed with CSL Limited, announced last year, says Thermo Fisher Scientific.
Pfizer Inc has started a trial to evaluate its investigational oral antiviral drug for the prevention of COVID-19 infection among those who have been exposed to the virus.
CyanVac LLC and its subsidiary, Blue Lake Biotechnology, Inc., have enrolled the first participant in a Phase 1 clinical trial of their intranasal COVID-19 vaccine in Rochester, NY.
Pfizer and BioNTech have released results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children aged 5 to 11 years old.
Adaptimmune Therapeutics, which focuses on solid tumors, has announced a tie-up with Roche's Genentech to develop and commercialize allogeneic cell therapies to treat multiple oncology indications.
Vaccitech has signed a lease for 31,000 sq. ft at Harwell Science and Innovation Campus in the UK, fitting out the facility with a state-of-the art wet laboratory and offices.
Anti-CD25 antibodies have emerged as promising next-generation cancer therapeutics, says US plant-based manufacturer of therapeutics and vaccines, iBio, as it enters the field.
The US National Institutes of Health (NIH) has begun a clinical trial to assess the antibody response to a COVID-19 vaccine booster in people with autoimmune disease who did not respond to an original COVID-19 vaccine regimen.
Johnson & Johnson has announced results from the primary analysis of its Imbokodo Phase 2b HIV vaccine clinical trial, with data showing the investigational HIV vaccine candidate did not provide sufficient protection against HIV infection. A Phase...
